EP1451319A2

EP1451319A2 - Method for identifying interaction partners using phage display

Info

Publication number: EP1451319A2
Application number: EP02807367A
Authority: EP
Inventors: Oliver Hill; Holger Ottleben
Original assignee: Graffinity Pharmaceuticals AG
Current assignee: Graffinity Pharmaceuticals AG
Priority date: 2001-11-28
Filing date: 2002-11-27
Publication date: 2004-09-01
Also published as: WO2003102591A2; DE10220593A1; AU2002367917A8; AU2002367917A1; DE10220602A1; US20050042598A1; WO2003102591A3

Abstract

The invention relates to a method for identifying and selecting interaction partners, which interact with a target molecule, with the aid of a support, to which anchor molecules are applied that form a polymer-free surface, to which affinity ligands are covalently bonded, said ligands being brought into contact with viruses that have a plurality of peptides or proteins as interaction partners on their surface. The inventive method guarantees an accumulation of viruses, which have specific interaction partners, by an optionally cyclic repetition of the selection. Optionally, selected specific interaction partners are expressed recombinantly once the coding nucleotide sequence has been identified. The invention also relates to a surface and its use for a phage display method.

Description

Procedure for identifying interaction partners using a phage display

The present invention relates to a method for the identification / selection of interaction partners which interact with a target molecule, using a carrier, on which anchor molecules are applied, which form a surface which is polymer-free and to which covalently bound affinity ligands are bound which are brought into contact with viruses that present a large number of peptides or proteins as interaction partners on their surface. The described method ensures, through a cyclical repetition of the selection, an enrichment of viruses that present specific interaction partners. According to the invention, selected specific interaction partners are optionally expressed recombinantly after identification of the coding nucleotide sequence. Furthermore, the invention comprises the surface described and the use thereof for a phage display method.

Various documents are cited in the text of this description. The disclosure content of the cited document (including all manufacturer descriptions, information etc.) is hereby part of this description by reference.

The identification of target molecules has led to the understanding of many biological processes. The usual experimental approaches so far have been cell-based screening and affinity chromatography. Although both techniques help target discovery, a method that couples protein identification to gene isolation is highly desirable. Such an approach is followed in a screening system in which in vitro gene expression techniques are combined with traditional biochemical approaches such as affinity chromatography. The functional gene selection takes place through a direct connection between the natural product affinity and the gene structure of the peptidic affinity ligand. Here, (non-) viral Peptides and proteins used as ligand, which are presented on the surface of recombinant viruses.

Phages are usually used for this method as an expression system for desired (non-) viral proteins or peptides. Phages are known to the person skilled in the art as viruses which specifically infect bacteria and are therefore not pathogenic to humans. In phage display genes coding for (non-) viral proteins or peptides are incorporated into the viral genome in such a way that fusion proteins are generated between the desired (non-) viral protein or peptide and a viral coat protein. As a result, when the virus replicates in the host, the fusion protein is presented on the surface of the virus. In a typical phage library for a phage display, a large number of DNA fragments which code for (non-) viral proteins or peptides are inserted into the viral genome. In this way, viral particles are generated that present a variety of proteins or peptides on the surface. A corresponding phage display library is then brought into contact with a sample immobilized on a support. In the subsequent washing step, phages that present fusion proteins that bind to the immobilized sample are retained on the support, whereas phages that present non-interacting fusion proteins are washed away. The bound phages are eluted and amplified by infection of a host culture. Repeated rounds of amplification and selection may be required to obtain a phage population that binds to the immobilized sample with high affinity. The inserted DNA sections are then sequenced from individual phage clones and the amino acid sequences of the binding proteins or peptides are derived therefrom.

Immobilization of the interaction partners (affinity ligands) is necessary to enable the separation of the phage-ligand complexes from the unbound phages.

Affinity ligands can be immobilized in a variety of ways. The corresponding procedure depends on various factors, such as the type of ligand or the carrier material. Immobilization can be covalent or by adsorption. A protein, very often an antibody, is usually used as the affinity ligand. However, in the prior art also describes the use of peptides or organic molecules as affinity ligands.

For affinity ligands that are proteins, methods are described in which these are immobilized directly on the carrier material by means of passive adsorption. A corresponding carrier material made of a polymeric plastic (e.g. polystyrene, polyvinyl, latex) and, for example, in the form of microtiter plates, membranes or spherical "leads ^" (quen / emitted polymers in particle form) is usually used for this purpose (Lowman, Annu. Rev. Biophys. Biomol. Struct. 26 (1997), 401-24). Butteroni et al. (J. Mol. Biol _r 304 (2000), 529-540), for example, adsorbed the Oct-4 protein in the presence of BSA (Bovine Serum Albumin) on microtiter plates.

A known disadvantage of an adsorptive immobilization of the affinity ligand is that the polymers used as carrier materials have a very high non-specific protein adsorption due to their hydrophobic properties. The exposed protein binding sites on the carrier must therefore be saturated with blocking reagents (e.g. BSA - Bovine Serum Albumin). As blocking agents, biopolymers such as e.g. Serum albumin, complex protein mixtures such as protein hydrolyzates (gelatin, trypthone), casein hydrolyzates, dry milk powder, polyamines and synthetic blocking reagents (e.g. polyvinylpyrolidone) can be used. Accordingly, there is a further disadvantage for such blocking reagents, since they also have non-specific protein binding.

A selection surface that can avoid the use of blocking reagents due to its low non-specific protein adsorption would therefore be more advantageous.

In addition, it is known that in the case of direct adsorption of proteins which are used as affinity ligands, these are partially denatured by direct contact with the carrier material. In this way, phages can be enriched in the selection process that specifically bind to the structure created by the denaturation. Furthermore, the immobilization of the affinity ligands by adsorption takes a very long time (several hours). With the above-mentioned direct adsorptive immobilization methods, only proteins can be used as affinity ligands for the phage display. This The fact severely limits the scope of phage display technology.

A reduction in the unspecific protein adsorption can be achieved in that there is no direct contact of the protein used as an affinity ligand with the carrier material. For this, anchor molecules are used, through which proteins are bound to the carrier. In this way, the native structure of the protein used as an affinity ligand can be obtained.

Accordingly, the use of antibodies directed against the ligand protein, which are adsorbed on the surface, is proposed in the prior art. The ligand protein is then immobilized according to this method via the specific antibody-antigen recognition. The prerequisite for this is that the antibody has a sufficiently high affinity for the ligand protein to be immobilized. Crameri et al. (Eur. J. Biochem. 226 (1994), 53-58), for example, immobilized anti-human IgE monoclonal antibodies in microtiter plates. By adding patient sera, immunoglobulins of the IgE class were bound as affinity ligands for the phage display. Consequently, the fact that antibodies against the affinity ligand used have to be elaborately generated before a corresponding method is a disadvantage of this method.

The use of anchor molecules also enables, in particular, the immobilization of small affinity ligands which, because of their molecular size, cannot themselves be immobilized via passive adsorption. Accordingly, methods are described according to which the immobilization of small molecules takes place by coupling to proteins that can be immobilized by adsorption. Dörsam et al. (FEBS Letters 414 (1997), 7-13) used steroids as covalent to BSA-coupled as small affinity ligands.

Other proteins frequently used as anchor molecules are streptavidin and avidin, which non-covalently bind the ubiquitous biotin (vitamin H) with high affinity (10 ^"15 M). This requires biotinylation of the affinity ligand, which is then attached via streptavidin or avidin The very slow dissociation rate of the biotin conjugated molecule enables the use of this system for the Affinity selection using phage display. (Griffiths and Duncan, Current Opinion in Biotechnology 9 (1998), 102-108). However, disadvantageous, non-specific interactions have also been described for the biotin-streptavidin / avidin system (for example with free sugar groups (Houen and Hansen, Journal of Immunological Methods 210 (1997), 115-123)). Another disadvantage arises from the fact that the binding of the biotinylated affinity ligand to the surface coated with streptavidin or avidin can be competed for by endogenous biotin of the host system.

When ligands are immobilized using streptavidin or avidin, the phage-ligand complexes are usually competitively detached from the affinity carrier by biotin. As a result, biotin is carried over to subsequent steps in the selection process and has to be removed in a time-consuming manner before another selection round. This is usually done by polyethylene glycol-mediated precipitation of the phages, precipitation and subsequent resumption in a biotin-free buffer system (Sehe et al., Chem. Biology 6 (1999), 707-716; Sehe et al., Chem. Biol. 8 (2001) , 399-400). Another disadvantage is that the affinity ligand first has to be biotinylated at great expense. Another major disadvantage of using proteins as anchor molecules is that unspecific protein binding to these anchor molecules occurs via protein-protein interactions. These non-specific protein bonds can be reduced by blocking reagents. However, the use of such blocking reagents again has the disadvantages described above.

Due to the non-covalent binding of the affinity ligand to the surface or the support material, all of the immobilization methods listed above only allow a competitive binding of the affinity ligand. This can lead to phage-ligand complexes detaching from the surface or the support material and therefore not being able to be selected.

In addition to the use of hydrophobic polymers such as polystyrene, the use of hydrophilic polymers such as Sepharose as a carrier material for the immobilization of affinity ligands has also been described. The advantage of hydrophilic polymers is that they are hydrophilic because of their Properties have a lower non-specific protein binding than hydrophobic polymers. Hydrophilic polymers that are used as carrier material for phage selection are natural or chemically modified polysaccharides such as dextrans, cellulose and nitrocellulose, queπ / wetted and / or pearled agarose (eg Sepharose), mixed matrices made of dextrans and highly cross-linked porous agarose (such as eg Superdex), as well as hydrogels made of polysaccharides or crosslinked Alϊyldextran / N, N-methylenebisacrylamide copolymers.

The attachment of the affinity ligand or a bond-mediating component (anchor molecule) to these hydrophilic polymers generally takes place in these processes by covalent coupling. An advantage of the covalent coupling is the more stable binding of the affinity ligand. The hydroxyl residues of polysaccharides, for example, can be activated by specific reagents (e.g. cyanogen bromide) so that amine-containing compounds can be covalently bound (Hermanson, Bioconjugate Techniques, Chapter 2.1, Academic Press, 1996).

Gram et al. (Eur. J. Biochem. 246 (1997), 633-637) describe the immobilization of Src homology 2) domains (SH2 domains) of an adapter protein Grb2 as a GST (glutathione-S-transferase) fusion protein on bromocyanine-activated Sepharose "Beads".

Hawlish et al. (Analytical Biochemistry 293 (2001), 142-145) describe the use of 15-mer peptides synthesized on cellulose membranes as affinity ligands. The initial coupling took place via a ß-Ala-ß-Ala dipeptide to the previously activated membrane.

An obvious disadvantage of the hydrophilic polymers mentioned is that they have a three-dimensional structure with cavities. The porous surface means that affinity ligands are not presented uniformly on the surface and are therefore not uniformly accessible. Other polymers with a porous surface used for phage selection are polyvinylidene fluoride (PVDF), (functionalized) nylon, polyethylene or polypropylene membranes. To avoid the described disadvantage of porous surfaces, polymer surfaces can be in the form of solid spherical particles such as, for example, acrylamide-bisacrylamide copolymers, polymethacrylates, polyethylene and polypropylene be used. When stacked, these solid particles can be used as affinity columns. Basically, spaces form between the solid spherical particles, in which dead volumes of phage suspension accumulate.

Another disadvantage of the immobilization of the affinity ligand on the abovementioned polymer surfaces is that, owing to the ligand density on the surface, which cannot be directly controlled, steric effects can occur between the relatively large phage particles and the polymer surface and between the protein or peptide expressed on the phage and the polymer surface. This can also lead to the identification of false positive interaction partners. The determination of an optimal density of the affinity ligand on the support material for the selection is very complex. In the case of passive adsorption, for example, the affinity ligand is diluted in different concentrations in the blocking reagent and brought into contact with an unknown number of coupling sites of the carrier material. This results in a competition of the affinity ligand with a dilution component contained in the blocking reagent for the bond-mediating groups of the support material. As a result, a surface layer is obtained which consists of a mixture of the affinity ligand and accompanying polymeric substances from the blocking reagent, e.g. BSA. In any case, the chemical properties of the surface are determined by the blocking reagent (variance of the chemical properties of the non-ligand-determined surface areas). Another disadvantage is that a very large amount of affinity ligand is required for the dilution series. This is particularly critical when the affinity ligand is only available in very small quantities and / or is very expensive. Accordingly, it is desirable to control the ligand density presented on the surface by the number of binding sites of the support material and not by the concentration of the affinity ligand in the blocking reagent during adsorption.

A surface where the ligand density can be controlled would therefore be an advantage. Another disadvantage of the above-mentioned polymer surfaces is that regeneration for further selection rounds is not possible or is very expensive. Reagents that make it possible to regenerate the surface in a one-step process (eg SDS-containing solutions or methanol-trifluoroacetic acid mixtures) cannot be used because they change or destroy the structure of the polymers. Likewise, the use of such reagents may lead to detachment of the polymers from the support. The use of proteins as anchor molecules also only allows the use of mild conditions for regeneration.

Accordingly, it would be advantageous to use a surface for phage selection that can be regenerated in a one-step process.

The present invention is therefore based on the technical problem of providing an easy-to-use method and an interface for a corresponding method for identifying / selecting specific interaction partners which avoid the disadvantages described above, i.e. for example that the surface should have a low protein adsorption and should be regenerable.

This technical problem is solved by the embodiments characterized in the claims.

Accordingly, the present invention relates to a method for the identification / selection of interaction partners, which interact with a target molecule, using a carrier onto which anchor molecules are applied, which form a surface which is polymer-free and to which covalently bound affinity ligands are attached, the method comprising the following steps:

(a) contacting the affinity ligands immobilized on the anchor molecules with viruses which present a large number of peptides or proteins as interaction partners on their surface;

(b) removing unbound viruses from the surface; and

(c) Evidence of an interaction between the affinity ligands and the interaction partners presented by the viruses. In the context of the present invention, the terms “identification” and “selection” mean an enrichment, preferably an individualization, of interaction partners. Consequently, the identification of interaction partners in a large population of any number of different interaction partners, as well as the selection of individual partners in a previously enriched population is included.

The term "interaction partner" is used in the context of the present invention to describe a population of molecules that includes molecules that interact with other molecules. The definition of the interaction partner thus includes peptides and proteins that interact with a target molecule.

An interaction can be characterized, for example, with a “key-lock principle”. The interaction partner (peptide or protein) and the target molecule (affinity ligand) have structures or motifs that match one another specifically, such as an antigenic determinant (epitope) that Knowing the structure of one of the interaction partners allows conclusions to be drawn about possible preferred structures or special structural elements of a suitable partner interacting therewith. In the method according to the invention, the interaction partners on the surface of viruses become peptides or proteins, which encompass all peptides or proteins whose coding nucleotide sequences can be inserted into a viral genome It is preferred that the expression of these peptides or proteins as part of the viral envelope is an assembly of this envelope and thus a propa virus allowed. The propagated virus is preferably infectious. The term peptides or proteins includes both natural and synthetic peptides or proteins. Examples of natural proteins include antibodies, antibody fragments, receptors that bind to their specific ligands, peptide ligands that interact with their specific receptors or peptide domains, that interact with specific substrates, including proteins and coenzymes, and other peptides or enzymes, etc. Also included are forms of the aforementioned proteins or peptides produced recombinantly. Correspondingly, natural peptides include, among other things, fragments of the proteins described above that are associated with specific ones Interact affinity ligands. Synthetic proteins or peptides include both pseudogenes or fragments thereof expressed as well as proteins or peptides with a random amino acid sequence. The peptides and proteins are thus preferably part of a library consisting of viruses, the viruses, preferably integrated into their genome, containing a nucleic acid sequence which codes for the corresponding peptide or protein. This nucleic acid sequence is typically present in such a way that, when expressed, it leads to the synthesis of the peptide or protein as part of a fusion protein which consists of a coat protein of the virus or a part thereof and of the peptide or protein. This fusion protein then has the ability to be localized on the surface of the virus and consequently to present the peptide or protein.

In connection with the method according to the invention, the term “affinity ligand” describes molecules or compounds which are immobilized on covalent bonds on anchor molecules described in more detail below. Accordingly, according to the invention, the term affinity ligand encompasses all substances and compounds to be immobilized on these anchor molecules with the present invention of the term "affinity ligand" includes organic and inorganic substances and compounds, for example also macromolecules and small molecules or small molecules. The term also includes both chemically unmodified and modified molecules.

The term "macromolecules" is understood to mean molecules with a high molecular complexity or a high molecular weight. These are preferably biomolecules, e.g. Biopolymers, especially proteins, oligo- or polypeptides, but also DNA, RNA, oligo- or polynucleotides, prosthetic groups, lipids, oligo- and polysaccharides, as well as their modifications, as well as synthetic molecules. In connection with proteins, receptors in particular come into consideration, but also proteins or peptides which represent epitopes or antigenic determinants of proteins. The proteins can also be fusion proteins.

The term “small molecules” or “low-molecular molecules” is understood to mean molecules which are of less molecular complexity than those above defined macromolecules. In the literature, the term “small molecules” or “low molecular weight molecules” (“Iow molecular weight molecules”) is not used uniformly. WO 89/03041 and WO 89/03042 describe molecules with molecular weights of up to 7000 g / mol as small molecules. Usually, however, molecular weights between 50 and 3000 g / mol are given, but more often between 75 and 2000 g / mol and mostly in the range between 100 and 1000 g / mol. Examples are known to the person skilled in the art from documents WO86 / 02736, WO97 / 31269, US-A-5928868, US-A-5242902, US-A-5468651, US-A-5547853, US-A-5616562, US-A-5641690 , US-A-4956303 and US-A-5928643. In the context of the present invention, the term “small molecules” is used for molecules (without anchors and without an additional molecule) with a molecular weight between 50 and 3000 g / mol, preferably between 75 and 1500 g / mol. Examples of such small molecules can be oligomers or small organic molecules, such as oligopeptides, oligonucleotides, carbohydrates (glycosides), isoprenoids or lipid structures. In the literature, molecular weight is mostly the basis for the definition of such small molecules.

The examples of the present application show that using the tetrapeptide Ac-pYVNV as affinity ligand from a human liver cDNA expression library (see Examples 1 to 7 below), three independent bacteriophage clones could be isolated, the capsids of which presented human protein fragments with sequence homologies to the SH2 domain , In connection with the present invention, the term “anchor molecules” describes compounds or molecules which serve as a connection between the affinity ligand and a support. According to the invention, they form a surface on the support which presents the affinity ligands on the side facing away from the support.

Anchor molecules which are suitable for the process according to the invention are characterized in that they form a surface on the support which is polymer-free. "Polymer-free" means that this surface does not include any polymers.

A polymer can be viewed as a substance made up of a multitude of molecules in which one or more types of atoms or Atomic groups (costing units) are repeatedly strung together, whereby the physical properties of the substance no longer change noticeably with a slight change in the number of building blocks. This is generally the case with polymers when their average molecular weight is at least 10,000 g / mol. Furthermore, polymers include biopolymers, such as. B. understood polypeptides comprising at least 50 amino acids. "Polymer-free" also preferably means that the anchor molecules which form the surface are not cross-linked to one another. It has surprisingly been found that the use of anchor molecules which form a polymer-free surface is particularly advantageous in a phage display process since they ensure a lower non-specific protein adsorption of the surface, and the use of blocking reagents can preferably be dispensed with.

The anchor molecules used in the method according to the invention preferably comprise at least two functional units which are present at opposite ends of the anchor molecule. One of these functional units serves to link the anchor molecules to the support (anchor group), the other serves to immobilize the affinity ligands. The latter is also referred to below as the "head group". Accordingly, the immobilization of an affinity ligand means the binding of this ligand to the head group of an anchor molecule. Such an anchor molecule is also characterized in that it is applied with its anchor group to a support. Affinity ligands are covalently bound to the head group of the anchor molecules. An example of an immobilization of affinity ligands by covalent binding to anchor molecules is described in Example 1 below. The advantage of the described binding of the affinity ligands to the anchor molecules is that the surface used for the selection, which is polymer-free, can be regenerated very easily. In the context of the present invention, regeneration means the complete removal of the phages or proteins bound to the surface. For this purpose, reagents that allow regeneration of the surface in a one-step process (for example SDS-containing solutions, formic acid or methanol-trifluoroacetic acid mixtures) can be used. One-step processes can be used for regeneration in the prior art used polymer surfaces are used only to a limited extent, since the reagents used change, destroy, or lead to the detachment of the polymers from the support. On the other hand, on the polymer-free surface used in the process according to the invention, the selection of the regeneration agents is restricted only with regard to the stability of the affinity ligand.

In connection with the present invention, the term “carrier” describes all phases to which a surface suitable for the method according to the invention can be applied. These phases are preferably solid phases. Examples of carriers that are suitable for the method according to the invention include solid carriers, which consist of one or more parts, the carriers are furthermore preferably characterized in that they comprise materials selected from the group consisting of glass, plastic, natural or synthetic membrane, metal, metal oxide or non-metal oxide In the case of the one-step process, the interaction partner / affinity ligand is linked to the head group of the anchor molecule before it is immobilized, and suitable anchor molecules for the one-step process are described in WO 0 0/73796 A2, where a complete ligand-anchor molecule conjugate (LAK) is applied to the surface to provide a measurement surface. It is a molecule that connects the affinity ligand to be immobilized and the functional group necessary for binding to the surface by means of a structure capable of SAM formation.

In the case of multi-stage processes, for example, a binding surface is first generated in the form of an organic boundary layer which does not yet present the desired specific structural features. However, this is characterized in that the affinity ligands can be bound to these directly or after their activation. To immobilize the affinity ligand, it is linked here, for example, only after a first, non-bond-specific boundary layer has been produced by means of a covalent bond defined above via the head group of the anchor molecules. The head group can do this can be used directly or after activation. A selection of such head groups is described in EP 485 874 A2.

The application of the affinity ligand to be immobilized is not limited to special processes. For more precise localization of the active sites on the bandage surface, conventional pipetting or spotting devices, for example, but also stamping or ink-jet methods can be used. Techniques for the described contacting of the affinity ligands immobilized on the anchor molecules with viruses which present a large number of peptides or proteins as interaction partners on their surface are known to the person skilled in the art. In addition, a possible method is described in the attached example 3. Other conditions are Inkontaktbringes. In the prior art example in T7Select ^® System Manual, Novagen, Madison (USA) (TB17806 / 00), pp 12ff described.

In a preferred embodiment of the invention, the anchor molecules form or are part of a highly ordered, self-assembled molecular monolayer. As a rule, self-organizing, highly ordered, uniform structures are formed at a phase boundary through generally hydrophobic interactions. Examples and preferred embodiments of such anchor molecules are described below.

In a further preferred embodiment of this method, the anchor molecule on which the affinity ligands are immobilized comprises an additional molecule which enhances the coupling of the affinity ligand to the anchor molecule. In the context of the present invention, the additional molecule is included in the anchor and must therefore also ensure the property of being polymer-free.

An example of such an additional molecule is cysteine. (For the introduction of a protected 2-aminoethylthiol on oligonucleotides, see D. Gottschling et al., Bioconjugate Chem. 9 (1998), 831-837.)

The additional molecule can additionally have the function of a spacer between the head group of the anchor molecule and the immobilized affinity ligand, as a result of which the latter is kept away from the head group and therefore their electronic and steric properties do not influence the binding properties of the interaction partner.

In a further, likewise preferred embodiment of the invention, the surface comprises, in addition to the anchor molecules, additional diluent molecules. These surface thinner molecules ensure that the spatial proximity of adjacent ligands can be controlled. This is achieved by not only applying anchor molecules to the support, but rather “diluting” them. If a ligand is bound to the surface for interaction analysis, adjacent ligands on the surface can influence one another or the interaction of the adjacent ligand with the interaction partner to be detected. In order to avoid such a steric hindrance, mixed surfaces are applied, which are composed of ligand-carrying anchor molecules as well as so-called diluent molecules which do not carry ligands and thus dilute the density of the anchor molecules in the surface. The concentration of the affinity ligand on the surface in the process according to the invention is preferably determined exclusively by the ratio of anchor to diluent molecules in the surface and not by the concentration of the ligand in the liquid to be applied, as is done according to the prior art. The diluent molecules should preferably be structurally such that they do not influence the interaction of the affinity ligand with the interaction partner presented on the virus. In addition, they are preferably characterized in that there are no specific or non-specific bonds between them and the interaction partners (e.g. thinners with the highest possible protein adsorption resistance). In addition, there is preferably as close a structural similarity as possible between the anchor molecule and the diluent molecule, in order to ensure that their mixing behavior on the carrier is as homogeneous as possible.

In a further preferred embodiment of the method according to the invention, the surface concentration of the affinity ligand is set via the ratio of anchor molecules to diluent molecules. A (dilute) surface concentration of affinity ligands is generated by chemical reaction of the affinity ligand to be immobilized with the head group of the anchor molecule. For this purpose, for example, the ligand-anchor molecule conjugate carries a thiol group in a one-step process. For example, for a two-step process, the affinity ligand has a thiol group that reacts with the head group of the anchor molecule (eg maleimide). The formation of a covalent bond with the head group of the anchor molecule is as selective and quantitative as possible (cf. Boeckler et al., J. Immun. Meth. 191 (1996), 1-10). If there is no suitable functional group in the corresponding molecules for these reactions, this can be generated by converting existing functional groups in the ligand to be immobilized. An example of this is a reductive cleavage of a disulfide bond to a thiol (Parham, J. Immunol. 131 (1983), 2895-2902). A thiol group, for example, can be used to connect the anchor molecules (and diluent molecules) to the support if a support with a gold surface is used.

In another preferred embodiment, the support is subdivided into individual regions, in each of which different affinity ligands are immobilized on the anchor molecules and thus a multiplicity of different ligands are bound to the respective anchor molecules of a support.

The unbound viruses in step (b) of the method according to the invention can be removed by conventional methods known to the person skilled in the art. The unbound viruses are preferably removed from the surface by elution. In accordance with the “specific interaction or interaction” defined above, the term “unbound viruses” encompasses viruses that do not specifically interact with the immobilized affinity ligand (s). An elution process is, for example, a washing process. Here, the surface can be treated, for example, with suitable solutions, the composition of which ensures that the specific interaction of the interaction partner with the target molecule is not resolved. In this context, differently stringent elution conditions are included, in which less strong, but still specific Interactions are resolved and there is thus an enrichment or identification of highly specific interacting interaction partners. An example of an elution procedure described in Example 3 below, further examples are known from the prior art, see for example in T7Select ^® System Manual, Fa. Novagen, Madison (USA) (TB178 06/00) S.14ff.

In a preferred embodiment, the method according to the invention further comprises a step (b ') which is carried out following step (b): (b ¹ ) multiplication of the bound viruses by infection of a host. Conditions for the multiplication of the bound viruses by infection of a host are described by way of example in the appended example 3. Appropriate conditions to those of skill but also from the state of the art and described inter alia in T7Select ^® System Manual, Fa. Novagen, Madison (USA) (TB178 06/00), page 18 et seq.

The method according to the invention further preferably comprises a step (b ") which is carried out after step (b '):

(b ") repeating step (a) with the increased virus population.

If step (a) is repeated following a multiplication of the viruses, a further selection round with an enriched virus population is carried out.

In a further preferred embodiment of the invention, steps (a) to (b ") are repeated a number of times before a specific interaction or interaction between the affinity ligands and the interaction partners presented by the viruses is detected in step (c). By repeating the steps (a) to (b ") a selective enrichment of viruses is guaranteed, the interaction partners of the immobilized affinity ligands present on their surface.

Evidence of the interaction between the affinity ligands and the interaction partners presented by the viruses according to step (c) of the The method according to the invention can be carried out by conventional methods known to the person skilled in the art.

In a preferred embodiment of the invention, the detection of the interaction between the affinity ligands and the interaction partners presented by the viruses in step (c) is based on an immunological, optical, vibration-based, radioactive or electrical method. The detection of the affinity ligand-virus interaction is possible with systems in which an indication system is coupled to the interaction partner / virus. This coupling can optionally take place in a further, additional method step. Such systems can be based on ELISA (Enzyme Linked Immunosorbent Assay), radioimmunoassay (RIA), surface plasmon resonance (SPR) or comparable measuring methods. Measurement methods based on optical phenomena are preferred. SPR measurements are particularly preferred, since no marking of the viruses is necessary for them.

In a further preferred embodiment, the specific interaction or interaction between the affinity ligands and the interaction partners presented by the viruses is carried out in step (c) without a label.

The specific interaction or interaction is also preferably detected optically by reflection. The interaction is preferably detected by determining the surface plasmon resonance (SPR). As already stated above, carriers for the process according to the invention consist, for example, of a metal, preferably a noble metal, particularly preferably of gold, or have a layer of such a metal on the surface. This metal layer can optionally be applied with the aid of an intermediate layer, which serves to promote adhesion. The material used to which the surface is applied depends on the measuring method used. If optical reflection methods such as surface plasmon resonance (SPR) are used, a support made of glass or plastic is preferred. When using sulfur-containing compounds for the immobilization of Ligands are preferably coated with a gold layer and a chrome layer to promote adhesion.

In another preferred embodiment, the method further comprises a step (i) which is carried out either after step (b ') and thus before a renewed selection round or after step (c): (i) Characterization of the binding of the selected virus populations as well as individual virus clones from these virus populations to the for the

Selection used affinity ligands in an assay. Any type of assay which is suitable for characterizing a binding can be considered as an assay. Such an assay is preferably a solid phase assay. An example of such a solid phase assay is described in Examples 4 and 5. Other methods known in the literature are ELISA (enzyme-linked immunosorbent assays), RIA (radioimmunoassay), and

Surface plasmon resonance (SPR) - or vibration resonance method (Butler, J.E., METHODS 22, 4-23 (2000).

The binding is also characterized according to the invention in step (i) on the same or identical surface on which the virus population and the individual virus clones originating from this virus population have been identified / selected.

For the first time, the method described here enables the use of surfaces with identical properties both for the selection process and for checking the binding behavior of the selected viruses, e.g. using SPR analysis. Houshmand et al. (Anal. Biochem. 268 (1999), 363-370) describe a phage display system in which a biosensor analysis was carried out. However, the surface used for the biosensor analysis differed in its properties from the surface used for the selection.

In a preferred embodiment, the interaction between the affinity ligands and the interaction partners (peptides / proteins) presented by the viruses is detected in step (c) on the surface on which the viruses have been identified / selected. The spatial configuration of the carrier for use in a method according to the invention is not restricted. For the detection of the interaction on the same surface on which the viruses were identified / selected, however, a planar, two-dimensionally extended structure is generally preferred. Depending on the field of application, three-dimensional shapes, such as spheres or hollow bodies, can also be used if necessary.

In addition, a preferred embodiment of the method further comprises step (d):

(d) Isolation and sequencing of the peptide or protein

Interaction partner coding DNA section of individual virus clones. Suitable methods are known to the person skilled in the art from the prior art which enable him to isolate and analyze the DNA sequences inserted into these, which code for the corresponding peptides or proteins, after the isolation of individual virus clones. A correspondingly suitable method is described in Example 6 below.

In a further preferred embodiment of the invention, the method further comprises the recombinant expression and isolation of the peptide or protein identified / selected as interaction partner of the affinity ligand.

An example of the recombinant expression of selected fusion proteins is described in Example 7 below. Various expression systems and thus further methods for the expression of isolated nucleic acid sequences and for the isolation of the encoded peptides and proteins are known to the person skilled in the art. These expression systems include prokaryotic and eukaryotic systems. (See also Chapter 9.4 Expression Systems in: Mühlhardt, The Experimentator: Molecular Biology Gustav Fischer Verlag 1999)

In another preferred embodiment, the method according to the invention further comprises characterizing the binding of the recombinantly expressed peptide or protein to that used for the selection Affinity ligands in an assay. The same assays are preferably used here as are used for checking the phage clones. This preferred embodiment ensures optimal comparability of the results. With the help of appropriate assays, for example, a virus-independent binding of the selected interaction partner can be detected.

In a further preferred embodiment of this method, this characterization takes place on the same surface that was used for the identification / selection of the corresponding virus.

Anchor molecules for a method according to the invention preferably correspond to the general formula

HS - R - M, where R is a structural element that ensures the structure of a SAM and M is a mercaptophile head group.

The radical R then preferably represents an unbranched or branched, optionally substituted, saturated or unsaturated hydrocarbon chain, which in turn can optionally be interrupted by heteroatoms, aromatics and heterocyclic compounds. The hydrocarbon chain preferably comprises 5-150 (chain) atoms, including heteroatoms. Anchor molecules are particularly preferred which have structures which make passive adsorption of the free interaction partner more difficult or avoid both on the anchor structure and on the measurement surface.

Suitable structural elements R, which both promote the formation of a monolayer and, if appropriate, also enable spacing groups (spacers) to be used to set suitable distances between the head groups and the support surface, are described for the anchor molecules in PCT publication WO 00/73796 A2, on the relevant ones Disclosure content is hereby fully referred to as a preferred embodiment of the method according to the invention.

Methods for synthesizing an anchor molecule can be carried out on a solid phase or in solution. When displaying in solution, preference is given to Provide a thiol group with a protective group. Suitable protective groups are described in TW Greene, PGM Wuts, Protective Groups in Organic Synthesis, Wiley 1999, Chapter 6, "Protection for the Thiol Group". In solid-phase synthesis, the coupling to the resin preferably takes place via the thiol group, so that this occurs during The cleavage from the solid phase or the protective group takes place in an acidic environment (for example 1% TFA in dichloromethane). In this way, side reactions of the thiol with the mercaptophil can be avoided.

A major advantage of the thiol / mercaptophil system is that the interaction partner to be immobilized can be bound under gentle reaction conditions (room temperature, pH-neutral, buffer solution can be used). This is particularly important for unstable compounds or proteins that easily denature. Another advantage is the fact that the thiol group is rarely found as a functionality compared to carboxylic acid, amine or amide residues in active ingredients. An undesired reaction between the mercaptophiles that may remain after immobilization of one interaction partner and the target can thus be largely avoided. In the thiol / maleiimide system in particular, a high selectivity in comparison to other functionalities, such as hydroxyl, amine, carboxyl or hydroxylamine groups, is also known. The formation of the covalent bond is also distinguished by a high reaction rate (cf. Schelte et al., Bioconj. Chem. 11 (2000), 118-123).

In particular when immobilizing a small affinity ligand, for example a so-called "small molecule", the selectivity and the quantitative course of the reaction are of the greatest importance for the quantitative evaluation of binding studies and interaction analyzes. In contrast to, for example, macromolecular recognition structures, small differences in the binding strength of these ligands with the interaction partners presented on the phages often have to be resolved here. A ligand of higher affinity, which is offered in a lower density (concentration) than another, weakly binding ligand, can lead to an artificially reduced signal and conversely, a weaker ligand which is offered in a higher density (concentration) leads to an artificially increased signal lead to another ligand. Furthermore, diluent molecules for the process according to the invention preferably correspond to the general formula

HS - R - X, where R is a structural element and X is a non-mercaptophile group. Here, the total chain length of the diluent molecule is preferably shortened compared to the anchor molecule, for example by one structural unit, such as an ethylene glycol unit. This can e.g. can be achieved in that the linear structure of the armature and the thinner on commercially available synthetic building blocks, the last building block in the thinner structure is omitted. In particular, the head group of the diluent molecule is preferably different from that of the anchor molecule. Preferred head groups for the diluent are methoxy and acylamide groups. Acetamide is particularly preferred, especially when maleimidyl is used as the anchor head group. To produce the surface, a solution of the anchor molecules is contacted with the carrier. Preferred, diluted measuring surfaces are obtained if a solution is used which contains a mixture of anchor and diluent molecules in a certain molar ratio.

In a preferred embodiment of the method according to the invention, the ratio of anchor molecules to diluent molecules is between 1: 2 and 1: 10000. Particularly preferred dilution ratios are in the range from 1:10 to 1: 100.

In a further preferred embodiment of this method, the total concentration of anchor molecule and dilution component is in a range from 0.001 to 100 mmol / l, particularly preferably approximately 0.1 to 1 mmol / l. Methods for producing such a homogeneous, large-area binding surface is described in German application DE 100 27 397.1. Reference is hereby made in full to the disclosure content of this application. The viruses carrying a large number of interaction partners and which are brought into contact with the affinity ligands in step (a) are more preferably used in different concentrations in solutions.

In another preferred embodiment of the method, the surface on which the affinity ligands are immobilized is organic and also serves as an anchor molecule. This preferably includes both a functional unit for linking the anchor molecules to the support (anchor group) and a functional unit for connecting the immobilized affinity ligands (head group).

An exemplary method for the immobilization of an affinity ligand on a self-assembling monolayer of anchor and diluent molecules is described in Example 1. This includes methods in which the affinity ligands are specifically bound to the anchor head groups directly or after activation.

The structural element R preferably further comprises a spacer. This spacer allows the overall chain length and flexibility of the ligand-anchor conjugate to be adjusted. A spacer of the structural element R for the process according to the invention preferably comprises an unbranched or branched hydrocarbon chain. According to the invention, this hydrocarbon chain can be saturated or unsaturated.

A structural element R for the method according to the invention further preferably has at least two structural subunits R ^a and R ^b . Even if only one of these subunits, preferably R ^a , is present, anchor molecules can already be provided which can be used for a method according to the invention. R ^a preferably causes the formation of a SAM. R ^a is also preferably hydrophobic. R ^a further preferably comprises an unbranched or a branched hydrocarbon chain. In addition, the hydrocarbon chains of the structural subunit R ^a are also preferably completely or partially unsaturated. The hydrocarbon chains preferably comprise 5 to 50 chain atoms which are optionally interrupted by aromatics, heterocycles or heteroatoms. In a preferred form, the hydrocarbon chains correspond to the general formula - (CH ₂ ) n-, where n is a natural number. This number preferably has a value from 5 to 50, preferably from 5 to 25, particularly preferably from 5 to 18 and most preferably from 8 to 12. It is further preferred that R ^a furthermore comprises functionalized alkanes. These are characterized in that they carry functional units on the end groups which are selected from a group comprising hydroxyl groups, halogen atoms, carboxylic acid groups and mercapto groups. These terminal functional units facilitate, for example, the connection to the neighboring structural units during the synthesis of the anchor molecules. With its help, necessary components of the anchor, in particular -SH groups, can optionally be introduced. These functionalized alkanes 11-mercaptoundecanoic acid or their derivatives are also preferred. Also preferred in this context are hydrocarbon chains which are interrupted by heteroatoms, aromatics and / or heterocyclic compounds.

The structural element R ^{b also} preferably comprises a distance harder. In addition, R ^b is preferably hydrophilic. R ^b further preferably comprises a hydrocarbon chain for the process according to the invention. In a further preferred embodiment of the invention, this hydrocarbon chain is interrupted by heteroatoms. The chain further preferably comprises between 10 and 100 chain atoms. The structural element R ^b in the process according to the invention likewise preferably comprises an oligoether or an oligoamide. The oligoamide is preferably composed of dicarboxylic acids and / or aminocarboxylic acids and diamines.

In a likewise preferred embodiment, the oligoether corresponds to the general formula

- (0 - Alk) _y - where y is a natural number and Alk is an alkylene radical. Y preferably has a value between 1 and 50, particularly preferably between 1 and 20 and most preferably between 2 and 10. The alkylene radical preferably has 1 to 20, particularly preferably 2 to 10 and particularly preferably 2 to 5 C atoms.

Preferably, the alkylene radical or the amines in the process according to the invention independently of one another comprise 1 to 20 C atoms, more preferably 2 to 10 and particularly preferably 2 to 5 C atoms. In addition, it is preferred that the structural element R ^b comprises residues which are interrupted by further heteroatoms, including O atoms.

In a further preferred embodiment, the oligoether corresponds to the general formula

- (- C ₂ H ₄ ) y - where y is a natural number.

In another preferred embodiment of the method, the natural number y has a value from 1 to 10.

For particularly preferred embodiments of R ^b , reference is made to the German application DE 100 27 397.1, the disclosure content of which is hereby fully incorporated by reference.

In a further preferred embodiment of the method according to the invention, the mercaptophilic head group M is selected from the group consisting of:

(a) iodine and bromoacetamides;

(b) pyridyldithio compounds;

(c) Michael acceptors;

(d) acrylic acid derivatives;

(e) esters, amides, lactones or lactams:

(f) methylene gem difluorocyclopropane;

(g) α, β-unsaturated aldehydes and ketones; and (h) α, β-unsaturated sulfones and sulfonamides. The head group M preferably corresponds to the general formula

where R ¹ to R ⁴ independently of one another represent hydrogen or C to C ₅ alkyl radicals or R ³ and R ⁴ together = 0. R ¹ and R ² are preferably independently of one another methyl, ethyl or n-propyl. The mercaptophilic head group M likewise preferably corresponds to a maleimidyl radical.

In a preferred embodiment, those presented by the viruses

Interaction partner encoded by DNA fragments inserted into the virus genome, which form a DNA library. The one included in the DNA library

Number of fragments, preferably at least 10 ³ , more preferably at least 10 ⁴ , in particular at least 10 ⁵ , preferably at least 10 ⁶ and very particularly preferably at least 10 ⁷ .

In a likewise preferred embodiment of the method, the inserted DNA fragments are isolated from cDNA or genomic DNA (gDNA) or are synthetic oligo- or polynucleotides. In addition, the inserted cDNA or inserted gDNA preferably originates from a prokaryotic or eukaryotic organism.

The eukaryotic organism is preferably a fungus, a plant or an animal organism, preferably a mammal. The mammal is preferably one

Mouse, rat or human.

In another preferred embodiment of the method, the cDNA is isolated from a differentiated tissue or a differentiated cell population.

Isolation of the cDNA from the liver, brain or heart is preferred

Breast tissue or cells. The tissues or cells preferably come from a healthy organism.

In an alternative preferred embodiment, the tissues or

Cells from a sick organism. The disease or suffering of the organism is preferably selected from the group consisting of cancer, hypertrophy and inflammation.

In a preferred embodiment, the virus system comprises a virus that

Uses eukaryotes as hosts.

In another preferred embodiment, the virus system comprises one

Virus that uses prokaryotes as hosts.

In a preferred embodiment of the method, the virus is selected from the group of viruses with double-stranded DNA (dsDNA viruses). This dsDNA virus is more preferably selected from the group of phages. In addition, the phage is preferably selected from the group of phages with tail, even more preferably selected from the group consisting of Myoviridae,

Podoviridae or Siphoviridae.

In a further preferred embodiment of the method, the phage is a bacteriophage specific for Escherichia coli.

In an alternative preferred embodiment of the method, the virus is selected from the group of viruses with single-stranded DNA (ssDNA viruses).

A virus system which is a lytic phage is also preferred. This lytic phage preferably has a polyhedral, in particular an icosahedral

Capsid.

In a preferred embodiment of the method, the lytic phage is a λ-

Phage, a T3 phage, a T4 phage or a T7 phage.

The described invention further comprises a carrier on which a surface used in the above-mentioned methods is applied. This surface is characterized in that it is polymer-free and comprises compounds (anchor molecules) to which covalently bound affinity ligands. The surface is also characterized in that viruses are bound to the affinity ligands immobilized on the surface. These viruses present the peptides or proteins as specific interaction partners of the affinity ligands on their surface, which interact specifically with the affinity ligands bound to the surface (see FIG. 2). This carrier according to the invention is preferably characterized in that the virus which presents peptides or proteins as interaction partner on the surface and which is specifically bound to the affinity ligands is bound to a host.

The same applies to the preferred embodiments of the carrier, the surface, the affinity ligands, the interaction partners and the viruses, as has already been said in connection with the method according to the invention.

The described invention further comprises the use of a support on which a surface is applied which is polymer-free and comprises anchor molecules to which covalently bound affinity ligands are used for a method according to the invention, preferably for a phage display method.

The figures show

Figure 1 Structural formulas of the compounds used to produce a polymer-free surface. The anchor molecule (A) used for the self-assembling monolayer (SAM) and the associated dilution component (B) as well as the affinity ligand (C) later coupled to the surface, which was chemically modified in this way, are shown that an intermediate molecule is attached to the N-terminus of the ligand, which enables coupling to the head group of the anchor by adding the thiol function to the double bond of the maleimidyl radical. In the context of the present invention, intermediate molecules are also included in the anchor and must therefore also ensure the property of being polymer-free.

Figure 2: Schematic representation of the interaction between that on the

Virus envelope exposed polypeptide and the immobilized

affinity ligands

A self-assembling monolayer is made on a solid support (1)

Anchor molecules and diluent molecules (2) applied. At the anchor molecules an affinity ligand (3) is covalently bound. Via the interaction partner (4) exposed on the virus envelope, the virus binds to the surface formed on the solid support by the anchor molecules and diluent molecules.

Figure 3: Sensogram of the binding of various phage lysates to the AcPYVNV sensor surface. The binding reactions were detected at a flow rate of 10 µl / min and a temperature of 25 ° C. HBS buffer (10 mM HEPES; 150 mM NaCl; 3 mM EDTA; 0.001% Tween 20, pH = 7.4) was used as the eluent. In each case, 200 ml of the lysates diluted in HBS were passed over the surface. (A) control lysate: DO = 174 RU; (B) Preparative lysate of the fourth round of selection: Do = 498 RU; (C) SDS pulse (20 μl 0.5% SDS in water) for regeneration of the sensor surface. In addition, the DO value (difference of the resonance signals before / after injection of the analyte) is identified as an example in measurement B. The start and end times of the injection are indicated by arrows.

Figure 4: Sequence of cDNA insertion from phages A4-28; A4-30; A4-40 in

5'-3 'orientation of the T710A gene used as a fusion partner. Flanking vector sequences are shown in italics. The translation product resulting from the reading frame of the coat protein is shown below the DNA sequence in the one-letter code. It corresponds to amino acids 174-340 of the human GRB 14 protein. The SH2 homologous sequence section (Src homology domain 2) is underlined and additionally identified by bold print.

Figure 5: Sequence of cDNA insertion from phages A4-26; A4-39 in 5'-3'-

Orientation of the T710A gene used as a fusion partner. Flanking vector sequences are shown in italics. The translation product resulting from the reading frame of the coat protein is shown below the DNA sequence in the one-letter code. It corresponds to amino acids 121-268 and 6-50 of p59fyn (T) = OKT3-induced calcium influx regulator. The SH2 homologous sequence section (Src homology domain 2) is underlined and additionally identified by bold print. Figure 6: Sequence of cDNA insertion from phage A4-37 in 5'-3'-

Orientation of the T710A gene used as a fusion partner. Flanking vector sequences are shown in italics. The translation product resulting from the reading frame of the coat protein is shown below the DNA sequence in the one-letter code. It corresponds to amino acids 614-724 of human phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (PIK3R1). The SH2 homologous sequence section (Src homology domain 2) is underlined and additionally identified by bold print.

FIG. 7: Sensogram of the binding of the recombinant p59Fyn-SH2 domain to the Ac-pYVNV sensor surface. The binding reactions were detected at a flow rate of 10 μl / min and a temperature of 25 ° C. HBS buffer (10 mM HEPES; 150 mM NaCl; 3 mM EDTA; 0.001% Tween 20) was used as the eluent. 100 μl of the recombinant protein diluted in HBS (c = 1 μM) were passed over the surface. D ₀ = 1673 RU. The start and end times of the injection are indicated by arrows.

The following examples illustrate the described invention.

Example 1: Immobilization of the affinity ligand

For the immobilization of the affinity ligand, gold surfaces on planar glass substrates (hereinafter referred to as chips) were mixed with a mixture of anchor molecule (1mM) and diluent molecule (1mM) (see FIGS. 1A and 1B), dissolved in methanol: trifluoroacetic acid (99: 1 v / v), in a ratio of 1:25 (v / v), hereinafter called the coating solution, for 60 minutes at room temperature to create the self-assembling organic monolayer. Subsequently, the surfaces were washed three times with a mixture of methanol: trifluoroacetic acid (TFA) (99: 1) to remove excess coating solution. Another washing step with 0.1% (v / v) TFA in water followed. It was then washed with 1 mM acetic acid in water and the surfaces dried in a stream of nitrogen. For the covalent coupling, a 40 μM solution of the affinity ligand Ac-pYVNV (cf. FIG. 1C) in 200 mM phosphate buffer (pH 7.0) was prepared and the coated gold surfaces were incubated in this solution for five minutes. The excess reagent was removed by washing the chips three times in 20 mM phosphate buffer (pH 7.0). The surfaces were dried again in a stream of nitrogen and stored at 4 ° C. until further use.

Example 2: Multiplication of the phage cDNA library

A commercially available human cDNA phage expression library based on the bacteriophage T7 was used for the biopanning (T7Select ™ Human Liver cDNA library; NOVAGEN, Madison (USA); Lot No. N14930). The number of primary clones was 1.7 x 10 ⁷ pfu (plaque forming units). Human liver tissue mRNA was used as the source of the cDNA fragments cloned into this library. The double strand cDNA fragments used for the cloning, synthesized from the mRNA by means of random priming, were fractionated according to size (300-3000 bp) and cloned into the 3 ^' terminus of the main coat protein gene (T7-10A gene) of the phage. The directional cloning pattern used by the company ensures that the inserted cDNA fragments are quantitatively oriented in the sense orientation to the T7-10A gene and thus the reading direction of the recipient and donor genes is identical. This leads to a higher number of phage clones with human protein fragments as fusion partners on the capsid. An assembly of intact viruses from the fusion protein alone is not possible due to steric hindrance by the fusion partner. The wild-type capsid protein, which is localized in a special host strain on a plasmid and is expressed after infection of the cell by the virus, is required for the formation of intact viral particles. In order to obtain a lysate suitable for the selection, 50 ml LB-Amp medium (10 g / l casein hydrolyzate, 5 g / l yeast extract, 5 g / l NaCl, 100 μg / ml ampicillin in H ₂ 0, pH 7.4) were inoculated with a single colony of the host strain (E.coli BLT5403), the cells were aerobically grown at 37 ° C. and the culture in the log phase was infected with 3 × 10 ⁸ pfu of the phage library at an OD600 = 0.32. At a OD600 = 0.32 there are approx. 1.2 x 10 ⁸ cfu (colony forming units) / ml in the culture; a total of 6 x 10 ⁹ cells were infected; the MOI (muftiplicy of infection; number of viruses / number of host cells) was 0.05. A low MOI was advantageous for the proliferation of the cDNA expression library in liquid culture, since it restricted a negative selection of slowly multiplying phage clones by limiting the multiplication cycles. Immediately after the lysis of the culture, protease inhibitors (final concentrations as follows: 2 μg / ml leupeptin; 1 mM PMSF (phenylmethylsulfonyl fluoride); 1 mM EDTA (ethylenediamine tetra-acetic acid) were added and the cell residues were sedimented (10000 x g / 15 min / 4 ° C.) The supernatant was then mixed with glycerin (10%, v / v), titrated and stored until use in the selection process at -80 ° C. The titer of the lysate thus produced was 8.6 × 10 ⁹ pfu / ml.

Example 3: Affinity selection of the cDNA phage expression library

For the first round of selection, six milliliters of the cDNA library lysate (5.16 x 10 ¹⁰ pfu total) with HBS buffer (10 mM HEPES; 150 mM NaCl; 3 mM EDTA; 0.001% Tween 20, pH 7.4) were added to 20 ml filled and brought into contact with a selection surface as described above. It was incubated for 20 min at room temperature with gentle agitation. The phage suspension was subsequently removed and the surface was washed seven times with 20 ml of TBST buffer (10 mM TRIS, 150 mM NaCl, 0.05% Tween 20, pH 7.4). The residual volume of the solution remaining after washing on the surface and in the vessel used had previously been determined to be 500 μl. Subsequently, a milliliter of a logarithmically growing host cell culture was placed on the selection surface (OD600 = 0.6-0.8) and left unmoved for ten minutes for infection with the phages adhering to the surface. The infected cells were mechanically detached by pipetting and diluted in a logarithmically growing 50 ml LB-Amp culture of the host strain (OD600 = 0.3). After the dilution, part of the culture was immediately removed and the number of infected cells titrated. Cultivation continued until the culture was completely lysed. Immediately after the lysis of the culture, protease inhibitors (final concentrations as follows: 2 μg / ml leupeptin; 1 mM PMSF; 1 mM EDTA) added and the cell residues sedimented (10000x g / 15 min / 4 ° C). The supernatant was then mixed with glycerin (10%, v / v) and stored at -80 ° C. until use in the second selection round. For the second round of selection, ten milliliters of the preparative lysate from the first selection were made up to 20 ml with HBS buffer and brought into contact with a new selection surface. The preparation of the chip and the implementation of the washing steps and the multiplication of the phages were carried out as described in Example 1. A total of four selection rounds were carried out. The following table provides information on the number of phages used in the selection rounds (input pfu) and the number of infection events (output pfu) that occurred after washing on the selection surface, as well as virus titers of the preparative lysates.

Selection: I. II. III. IV.

Input pfu: 5.0 x 10 ¹⁰ 2.0 x 10 ¹¹ 5.2 x 10 ¹¹ 6.0 x 10 ¹¹

Infected cells (output pfu): 2.5 x 10 ⁴ 2.52 x 10 ⁵ 1, 47 x 10 ⁶ 6.75 x 10 ⁵ titer of the preparative lysate: 2.0 x 10 ¹⁰ 5.2 x 10 ¹⁰ 6, 0 x 10 ¹⁰ 4.2 x 10 ¹⁰

Tab. 1. Control of phage input / output

Example 4: Checking the binding behavior of the lysates using SPR measurement

The binding behavior of the selected phages against the immobilized affinity ligand was checked by detecting the surface plasmon resonance (SPR - Surface Plasmon Resonance) in a BIACORE ^® 3000 device (Biacore AB, Uppsala, Sweden). A Pioneer J1 chip from Biacore was used for this purpose.

The affinity ligand was immobilized as described in Example 1. The various phage suspensions from the selection process served as analytes. From the subsequent time-resolved measurement of the surface plasmon resonance, the relative affinity of the selected phages towards the immobilized ligand could be derived directly. For this, the Difference formed between the resonance signal after the end of the analyte injection and the resonance signal before the start of the analyte injection (Do value) and compared with the corresponding control measurement (negative control) (see FIG. 3). Phage suspensions with binders had an increased D ₀ compared to the negative control.

The titers of the lysates to be examined were determined in advance in order to ensure approximately the same number of phages per measurement. The titers of the preparative lysates obtained in the screening were usually between 2 × ^{10 10} and ⁶ × ^{10 10} pfu / ml (see Table 1). Lysates with phage titers of this size were considered to be comparable. The phages were bound to the measurement surface at a constant flow rate. All measurements were carried out on the same Ac-pYVNV chip. The surface was regenerated between measurements using SDS denaturation of the phage / ligand interaction. For this, 20-30μl 0.5% (w / v) SDS (sodium dodecyl sulfate) were injected in water.

Lysate: D „(RU) titer (pfu)

Selection I. 205 2.0 x 10 ¹⁰

Selection II. 179 5.2 x 10 ¹⁰

Selection III. 210 6.0 x 10 ¹⁰

Selection IV. 498 4.2 x 10 ¹⁰

Control 174 4.3 x 10 ¹⁰

Tab. 2: Results of the SPR measurements with the preparative lysates of the primary selection

The phage lysates were usually diluted 1:10 in HBS buffer and clarified in the centrifuge immediately before the injection (20,000 × g; 4 ° C., 5 min). For the measurement of the lysates obtained in the selection process, 200 μl of the dilution were injected at a flow of 10 μl / min. The binding behavior of the lysates was assessed as positive if the D ₀ value obtained in the measurement was more than 40% above the measurement value achieved with the negative control under identical conditions. As a negative control, a phage lysate with initial 79000 clones prepared from the acquired cDNA library. The titer of this lysate was 4.3 x 10 ¹⁰ pfu / ml. FIG. 3 shows an example of the evaluation of one of the sensograms obtained.

The Do value of the preparative lysate from the fourth round of selection suggested an accumulation of binding partners through the selection process.

Example 5: Secondary selection process: selection via relative affinity measurements

In order to be able to assess the selection process with regard to the increase in binders within the phage population, lysates defined in the number of clones were created, i.e. lysates were grown that resulted from infection of a host culture with only ten individual phage clones from the screening process.

These clones were isolated by cutting out and washing away individual plaques. For this purpose, the titer plates were used, which were prepared for titrating the host cells infected on the surfaces. Each plaque on these plates corresponded to a phage clone that had stuck to the chip surface after the selection procedure and had led to an infection event. The combined lysates obtained in this way were characterized by SPR measurement in their binding behavior with respect to the affinity ligand, as explained under 4. Deviating from the procedure described under 4., the injection volume of the phage suspensions was reduced to 50 μl. On the basis of the detection of binding phages following the fourth selection round (see Table 2), four phage lysates with 10 clones each were prepared and measured from the titer plates of the fourth selection round as described.

Two of these pools (Pool 3 and Pool 4) showed a positive binding behavior towards the affinity ligand compared to the control. The 20 phage clones of these two pools were grown individually and the lysates were characterized as described by means of time-resolved SPR measurement with regard to their binding behavior towards the Ac-pYVNV sensor surface. Six clones proved to be positive binders with respect to the affinity ligand.

Lysate: Do (RU) titer (pfu)

Pool 1. (Clone A4-1 to A4-10) 92 2.9 x 10 ¹⁰

Pool 2. (Clone A4-11 to A4-20) 99 4.2 x 10 ¹⁰

Pool 3 (Clone A4-21 to A4-30) 159 5.0 x 10 ¹⁰

Pool 4 (Clone A4-31 to A4-40) 203 4.5 x 10 ¹⁰

Control 75 4.3 x 10 ¹⁰

Tab. 3. Results of the SPR measurements with the preparative lysates of the defined phage pools from the fourth selection round

Lysate: D ₀ (RU) titer (pfu)

Clon-A4-26 596 5.3 x 10 ¹⁰

Clon-A4-28 334 6.6 x 10 ¹⁰

Clon-A4-30 246 1.6 x 10 ¹⁰

Clon-A4-37 168 2.6 x 10 ¹⁰

Clon-A4-39 396 1.6 x 10 ¹⁰

Clon-A4-40 426 6.3 x 10 ¹⁰

Control 75 4.3 x 10 ¹⁰

Tab. 4. Results of the SPR measurements of the phage clones identified as positive binders

Example 6: Analysis of the cDNA insertions of positive single clones

Of the individual clones identified under 5 as positive binders, the sequence section coding for the fusion portion was amplified by means of PCR from a single plaque. For this, oligonucleotides were used which flank the Hybridize passenger DNA in vector. The amplification products were purified, the nucleotide sequence was determined using customary methods and the sequence data obtained were first compared with one another. It was found that the cDNA insertions of several phages were identical. Three independent cDNA insertions could be identified in the sequenced phage pool.

The homologous genes were subsequently identified using BLAST research on the NCBI server:

Insertion-1: represented by clones A4-28; A4-30; A4-40 (see. Figure 4). The insertion partially matches the sequence from the GenBank entry XM_010770. Definition: Homo sapiens growth factor receptor-bound protein 14 (GRB14), mRNA.

Insertion-Il: represented by the clones A4-26; A4-39 (see. Figure 5). The insertion partially matches the sequence from GenBank entry S74774. Definition: p59fyn (T) = OKT3-induced calcium influx regulator [human, Jurkat J6 T-cell line, mRNA partial, 1605 nt.

Insertion-HI: represented by clone A4-37 (see. Figure 6). The insertion partially matches the sequence from the GenBank entry XM_043864. Definition: Homo sapiens phosphoinositide-3-kinase, regulatory subunit, poiypeptide 1 (p85 alpha) (PIK3R1), mRNA.

In order to identify known protein domains, a homology search was then carried out with the translation product of the cloned cDNA sequences resulting from the reading frame of the coat protein gene. Surprisingly, it was found that all the sequenced cDNA insertions in the reading frame of the coat protein code for human proteins which contained SH2-homologous sequence segments in their primary sequence.

Example 7: Recombinant expression of the selected fusion proteins

In order to demonstrate the specificity of the binding of the identified proteins to the immobilized ligand, the identified proteins were included usual methods recombinantly expressed and purified in E. coli. Subsequently, the binding behavior of the recombinant proteins to the selection surface was analyzed using a time-resolved SPR measurement in the Biacore ^® 3000. All measurements were carried out on the Ac-pYVNV chip, which was also used for the analysis of the phage suspensions. The binding behavior of the recombinantly expressed p59 (fyn) -SH2 domain towards the immobilized affinity ligands Ac-pYVNV- is shown as an example in FIG. The other recombinantly expressed proteins also showed a positive binding behavior towards the immobilized ligand.

Claims

Expectations

1. A method for identifying / selecting interaction partners that interact with a target molecule, using a support, onto which anchor molecules are applied, which form a surface which is polymer-free, and to which covalently bound affinity ligands, the method comprising includes the following steps:

(b) removing unbound viruses from the surface; and

(c) Evidence of an interaction between the affinity ligands and the interaction partners presented by the viruses.

2. The method according to claim 1, wherein the anchor molecules form or are part of a highly ordered, self-assembled molecular monolayer.

3. The method of claim 1 or 2, wherein the highly ordered, self-assembled molecular monolayer additionally comprises diluent molecules.

4. The method according to any one of claims 1 to 3, wherein the surface concentration of the affinity ligand is adjusted via the ratio of anchor molecules to diluent molecules.

5. The method according to any one of claims 1 to 4, wherein the carrier is divided into individual areas in which different affinity ligands are immobilized on the anchor molecules and thus a variety of different ligands are bound to the respective anchor molecules of a carrier.

6. The method according to any one of claims 1 to 5, wherein the unbound viruses are removed from the surface by elution.

7. The method according to any one of claims 1 to 6, further comprising a step (b ') following step (b):

(b ') multiplying bound viruses by infection of a host.

8. The method according to any one of claims 1 to 7, further comprising a step (b ") following step (b '):

(b ") repeating step (a) with the increased virus population.

9. The method according to claim 8, wherein steps (a) to (b ") are repeated several times before a specific interaction or interaction between the affinity ligands and the interaction partners presented by the viruses in step (c) is detected.

10. The method according to any one of claims 1 to 9, wherein macromolecules are used as affinity ligands.

11. The method according to claim 10, wherein the macromolecules are selected from the group consisting of:

(a) oligo- or polypeptides;

(b) oligonucleotides or polynucleotides;

(c) prosthetic groups;

(d) lipids; and

(e) oligo- and polysaccharides.

12. The method according to any one of claims 1 to 9, wherein low molecular weight molecules are used as affinity ligands.

13. The method of claim 12, wherein the low molecular weight molecules are inorganic molecules.

14. The method of claim 12, wherein the low molecular weight molecules are organic molecules.

15. The method according to any one of claims 1 to 14, wherein the detection of the specific interaction or interaction between the affinity ligands and the interaction partners presented by the viruses in step (c) is based on an immunological, optical, vibration-based, radioactive or electrical method.

16. The method according to any one of claims 1 to 15, wherein the detection of the specific interaction or interaction between the affinity ligands and the interaction partners presented by the viruses in step (c) is carried out without a label.

17. The method according to claim 15 or 16, wherein the detection of the specific interaction or interaction is carried out by reflection optics.

18. The method according to claim 17, wherein the detection of the specific interaction or interaction is characterized in that the surface plasmon resonance (SPR) is determined.

19. The method according to any one of claims 1 to 18, further comprising step (i) which is carried out either following step (b ') or step (c):

(i) Characterization of the binding of the selected virus populations and individual virus clones originating from these virus populations on the affinity ligands used for the selection in an assay.

20. The method according to claim 19, wherein the characterization of the binding in step (c) takes place on the same or identical surface on which the virus population and the individual virus clones originating from this virus population have been identified / selected.

21. The method according to any one of claims 1 to 20, wherein the detection of the specific interaction or interaction between the affinity ligands and the interaction partners presented by the viruses (peptides / proteins) in step (c) on the surface on which the viruses are identified / selected were.

22. The method according to any one of claims 1 to 21, further comprising step (d):

(d) Isolation and sequencing of the DNA section coding for the peptide or protein of the interaction partner of individual virus clones.

23. The method according to any one of claims 1 to 22, further comprising the recombinant expression and isolation of the peptide or protein identified / selected as an interaction partner of the affinity ligand.

24. The method of claim 23, further comprising characterizing in an assay the binding of the recombinantly expressed peptide or protein to the affinity ligand used for the selection.

25. The method according to any one of claims 1 to 24, wherein the anchor molecules of the general formula

HS - R - M correspond, where R is a structural element which ensures the structure of a SAM and M represents a mercaptophile head group.

26. The method according to any one of claims 3 to 25, wherein the diluent molecules of the general formula

HS - R - X correspond, where R is a structural element and X is a non-mercaptophile group.

27. The method according to claim 26, wherein the ratio of anchor molecules to diluent molecules is between 1: 2 and 1: 10000.

28. The method according to any one of claims 1 to 27, wherein the viruses which carry a large number of interaction partners and which are brought into contact with the affinity ligands in step (a) are used in different concentrations in solutions.

29. The method according to any one of claims 1 to 28, wherein the surface on which the affinity ligands are immobilized is an organic, which also serves as an anchor molecule and both a functional unit for linking the anchor molecules with the support (anchor group), as well as a functional Unit for binding the immobilized affinity ligands (head group) comprises.

30. The method according to any one of claims 25 to 29, wherein the structural element R further comprises a spacer.

31. The method according to any one of claims 25 to 29, wherein the structural element R has at least two structural subunits R ^a and R ^b .

32. The method of claim 31, wherein R ^{a is} hydrophobic.

33. The method of claim 31 or 32, wherein the structural element R ^b comprises a spacer.

34. The method according to any one of claims 31 to 33, wherein R ^{b is} hydrophilic.

35. The method according to any one of claims 21 to 30, wherein the head group M of the general formula

corresponds, where R ¹ to R ⁴ independently of one another are hydrogen or Cr to C ₅ alkyl radicals or R ³ and R ⁴ together = O.

36. The method according to any one of claims 25 to 34, wherein the mercaptophilic head group M is a maleimidyl radical.

37. The method according to any one of claims 1 to 36, wherein the interaction partners presented by the viruses are encoded by DNA fragments inserted into the virus genome, which form a DNA library.

38. The method according to claim 37, wherein the number of fragments contained in the DNA library is at least X, where X is selected from the group consisting of 10 ³ , 10 ⁴ , 10 ⁵ , 10 ⁶ and 10 ⁷ .

39. The method of claim 37 or 38, wherein the inserted DNA fragments are isolated from cDNA or genomic DNA (gDNA) or are synthetic oligo- or polynucleotides.

40. The method of claim 39, wherein the inserted cDNA or gDNA is from a prokaryotic organism.

41. The method of claim 39, wherein the inserted cDNA or gDNA is from a eukaryotic organism.

42. The method of claim 41, wherein the eukaryotic organism is a fungus.

43. The method of claim 41, wherein the eukaryotic organism is a plant or an animal organism.

44. The method of claim 43, wherein the animal organism is a mammal.

45. The method of claim 44, wherein the mammal is a mouse, rat, or human.

46. The method of claim 44 or 45, wherein the cDNA is isolated from a differentiated tissue or a differentiated cell population.

47. The method of claim 44 to 46, wherein the cDNA is isolated from liver, brain, heart or breast tissue or cells.

48. The method according to any one of claims 44 to 47, wherein the tissue or the cells come from a healthy organism.

49. The method according to any one of claims 44 to 47, wherein the tissue or the cell originate from a sick organism.

50. The method of claim 49, wherein the disease or disorder of the organism is selected from the group consisting of cancer, hypertrophy or inflammation.

52. The method according to any one of claims 1 to 50, wherein the virus system comprises a virus that uses eukaryotes as a host.

53. The method according to any one of claims 1 to 50, wherein the virus system comprises a virus that uses prokaryotes as hosts.

54. The method of claim 53, wherein the virus is selected from the group of viruses with double-stranded DNA (dsDNA viruses).

55. The method according to claim 54, wherein the dsDNA virus is selected from the group of phages.

56. The method of claim 55, wherein the phage is selected from the group of phages with tail.

57. The method of claim 56, wherein the phage is selected from a group comprising Myoviridae, Podoviridae or Siphoviridae.

58. The method according to any one of claims 55 to 57, wherein the phage is a bacteriophage specific for Escherichia coli.

59. The method of claim 53, wherein the virus is selected from the group of viruses with single-stranded DNA (ssDNA viruses).

60. The method according to any one of claims 55 to 59, wherein the virus system is a lytic phage.

61. The method of claim 60, wherein the lytic phage has an icosahedral capsid.

62. The method of claim 60 or 61, wherein the lytic phage is a λ phage, a T3 phage, a T4 phage or a T7 phage.

63. Support on which a surface is applied, which is characterized in that it is polymer-free and comprises compounds (anchor molecules) to which covalently bound affinity ligands, and where bound to the affinity ligands are viruses which use peptides or proteins as specific interaction partners of the Present affinity ligands on their surface.

64. Carrier according to claim 63, characterized in that the peptide or protein as interaction partner on the surface presenting virus, which is specifically bound to the affinity ligands, is bound to a host.

5. Use of a support on which a surface is applied which is characterized in that it is polymer-free and comprises compounds (anchor molecules) to which covalently bound affinity ligands are used for a process according to one of claims 1 to 62.